Progress on the role mechanism, diagnostic value and prognosis of alpha fetoprotein in hepatoid adenocarcinoma of the stomach

doi:10.3877/cma.j.issn.1674-0793.2023.05.012

Abstract

Abstract:

Hepatoid adenocarcinoma of the stomach (HAS) is a special subtype of gastric cancer, which is a rare malignant tumor with both adenocarcinoma and hepatocellular carcinoma-like differentiation, and most patients have elevated serum alpha fetoprotein (AFP). However, the value of AFP in HAS is still unclear. In order to further deepen the comprehensive understanding of AFP in HAS and to understand its clinical significance, the role mechanism, diagnostic value and prognosis of AFP are reviewed for accurate diagnosis and treatment of HAS in clinics.

Key words: Hepatoid adenocarcinoma of the stomach, Alpha fetoprotein, Diagnosis, Prognosis

Qing Lan, Zhifan Xiong, Shengli Yang. Progress on the role mechanism, diagnostic value and prognosis of alpha fetoprotein in hepatoid adenocarcinoma of the stomach[J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 376-379.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2023.05.012

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2023/V17/I05/376

Figures/Tables 2

References 35

[1]	Xia R, Zhou Y, Wang Y, et al. Hepatoid adenocarcinoma of the stomach: current perspectives and new developments[J]. Front Oncol, 2021, 11: 633916.
[2]	Meng W, Bai B, Bai Z, et al. The immunosuppression role of alpha-fetoprotein in human hepatocellular carcinoma[J]. Discov Med, 2016, 21(118): 489-494.
[3]	Zhang C, Zhang J, Wang J, et al. Alpha-fetoprotein accelerates the progression of hepatocellular carcinoma by promoting Bcl-2 gene expression through an RA-RAR signalling pathway[J]. J Cell Mol Med, 2020, 24(23): 13804-13812.
[4]	Bourreille J, Metayer P, Sauger F, et al. Existence of alpha feto protein during gastric-origin secondary cancer of the liver[J]. Presse Med (1893), 1970, 78(28): 1277-1278.
[5]	Ishikura H, Fukasawa Y, Ogasawara K, et al. An AFP-producing gastric carcinoma with features of hepatic differentiation. A case report[J]. Cancer, 1985, 56(4): 840-848.
[6]	Zhang Y, Han S, Lv L, et al. Case report: A rare case of hepatoid adenocarcinoma in stomach and duodenum simultaneously[J]. Cancer Manag Res, 2022, 14: 2185-2191.
[7]	Zhou Q, Zhou Y, Ouyang Y, et al. Hepatoid adenocarcinoma of the stomach with metastatic choriocarcinoma of the liver: A case report of a rare subtype of gastric cancer with a complex treatment course[J]. Front Surg, 2022, 9: 968891.
[8]	Osada M, Aishima S, Hirahashi M, et al. Combination of hepatocellular markers is useful for prognostication in gastric hepatoid adenocarcinoma[J]. Hum Pathol, 2014, 45(6): 1243-1250.
[9]	王祥旭, 潘伟, 博伦, 等. 35例胃肝样腺癌的临床病理观察[J]. 临床肿瘤学杂志, 2021, 26(3): 243-247.
[10]	赵荣飞, 王鑫鑫, 蓝忻, 等. 胃肝样腺癌临床病理特征及预后分析[J]. 中华胃肠外科杂志, 2017, 20(9): 1035-1039.
[11]	任为正, 苏茂生, 杜晓霞, 等. 胃肝样腺癌25例[J]. 中华肝胆外科杂志, 2016, 22(10): 665-667.
[12]	Liu XM, Chen GQ, Li SL, et al. Hepatoid adenocarcinoma of the stomach: A case report and literature review[J]. Exp Ther Med, 2015, 9(6): 2133-2136.
[13]	Su JS, Chen YT, Wang RC, et al. Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: A literature review[J]. World J Gastroenterol, 2013, 19(3): 321-327.
[14]	张琛琛, 于伟华, 杜亚婷, 等. 胃肝样腺癌的临床病理特点及预后分析[J]. 中国现代普通外科进展, 2022, 25(7): 543-547.
[15]	Wang Y, Sun L, Li Z, et al. Hepatoid adenocarcinoma of the stomach: A unique subgroup with distinct clinicopathological and molecular features[J]. Gastric Cancer, 2019, 22(6): 1183-1192.
[16]	Chen EB, Wei YC, Liu HN, et al. Hepatoid adenocarcinoma of stomach: emphasis on the clinical relationship with alpha-fetoprotein-positive gastric cancer[J]. Biomed Res Int, 2019, 2019: 6710428.
[17]	Inoue M, Sano T, Kuchiba A, et al. Long-term results of gastrectomy for alpha-fetoprotein-producing gastric cancer[J]. Br J Surg, 2010, 97(7): 1056-1061.
[18]	Lin JX, Wang ZK, Hong QQ, et al. Assessment of clinicopathological characteristics and development of an individualized prognostic model for patients with hepatoid adenocarcinoma of the stomach[J]. JAMA Netw Open, 2021, 4(10): e2128217.
[19]	邵国益, 张献, 胡根, 等. AFP阳性胃肝样腺癌15例临床分析[J]. 现代肿瘤医学, 2015, 23(21): 3154-3157.
[20]	李晨, 夏绍友, 张勇. 胃肝样腺癌血清甲胎蛋白阳性的临床意义[J]. 中国医药导报, 2012, 9(6): 43-45, 48.
[21]	Lin Y, Yang Y, Li W, et al. Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells[J]. Mol Cell, 2012, 48(4): 627-640.
[22]	Zhao QW, Zhou YW, Li WX, et al. Akt-mediated phosphorylation of Oct4 is associated with the proliferation of stem-like cancer cells[J]. Oncol Rep, 2015, 33(4): 1621-1629.
[23]	Zhu M, Guo J, Li W, et al. HBx induced AFP receptor expressed to activate PI3K/AKT signal to promote expression of Src in liver cells and hepatoma cells[J]. BMC Cancer, 2015, 15: 362.
[24]	Li MS, Li PF, He SP, et al. The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel7402 cell line[J]. World J Gastroenterol, 2002, 8(3): 469-475.
[25]	Li M, Mei YX, Wen JH, et al. Hepatoid adenocarcinoma-clinicopathological features and molecular characteristics[J]. Cancer Lett, 2023, 559: 216104.
[26]	Gálvez-Muñoz E, Gallego-Plazas J, Gonzalez-Orozco V, et al. Hepatoid adenocarcinoma of the stomach - a different histology for not so different gastric adenocarcinoma: A case report[J]. Int Semin Surg Oncol, 2009, 6: 13.
[27]	陆泳言, 姜文凯, 李硕, 等. 甲胎蛋白阳性胃癌的分子机制与诊疗现状[J]. 临床与病理杂志, 2022, 42(9): 2255-2261.
[28]	Rajasekaran P, Pattnaik B, Mishra M, et al. Alpha-fetoprotein (AFP)-negative hepatoid adenocarcinoma of the stomach and its associated uncommon features with a review[J]. Int J Surg Pathol, 2022: 10668969221142038.
[29]	Nagai E, Ueyama T, Yao T, et al. Hepatoid adenocarcinoma of the stomach. A clinicopathologic and immunohistochemical analysis[J]. Cancer, 1993, 72(6): 1827-1835.
[30]	于丽丽, 何向蕾, 吴建宇, 等. GPC3、HSP70、SALL4和AFP联合表达对胃肝样腺癌诊断的意义[J]. 浙江医学, 2020, 42(8): 780-782, 786, 884.
[31]	刘鑫, 温宗华, 张国, 等. 胃肝样腺癌6例临床资料分析[J]. 临床消化病杂志, 2017, 29(3): 155-158.
[32]	Metzgeroth G, Ströbel P, Baumbusch T, et al. Hepatoid adenocarcinoma-review of the literature illustrated by a rare case originating in the peritoneal cavity[J]. Onkologie, 2010, 33(5): 263-269.
[33]	Chen Y, Qu H, Jian M, et al. High level of serum AFP is an independent negative prognostic factor in gastric cancer[J]. Int J Biol Markers, 2015, 30(4): e387-e393.
[34]	Lin HJ, Hsieh YH, Fang WL, et al. Clinical manifestations in patients with alpha-fetoprotein-producing gastric cancer[J]. Curr Oncol, 2014, 21(3): e394-e399.
[35]	He F, Fu Y, Sun Q, et al. Integrated clinicopathological and immunohistochemical analysis of gastric adenocarcinoma with hepatoid differentiation: An exploration of histogenesis, molecular characteristics, and prognostic markers[J]. Hum Pathol, 2021, 115: 37-46.

第一作者	发表年	血清阳性率	IHC阳性率
王祥旭^[9]	2021	37.5	44.8
赵荣飞^[10]	2017	41.7	─
任为正^[11]	2016	56.0	─
Liu^[12]	2015	88.9	─
Su^[13]	2013	84.8	91.6
张琛琛^[14]	2022	42.9	42.9

第一作者	发表年	血清阳性率	IHC阳性率
王祥旭^[9]	2021	37.5	44.8
赵荣飞^[10]	2017	41.7	─
任为正^[11]	2016	56.0	─
Liu^[12]	2015	88.9	─
Su^[13]	2013	84.8	91.6
张琛琛^[14]	2022	42.9	42.9

Please choose a citation manager

Content to export